The Limbic

TSANZ says new evidence strengthens case against vaping for smoking cessation

Respiratory experts have urged parliament not to ease access to electronic cigarettes, saying new evidence has confirmed that vaping has little benefit in tobacco smoking cessation and harms the lungs. Professor Matthew Peters, Professor of Respiratory Medicine, Macquarie University, Sydney, has...

Respiratory experts have urged parliament not to ease access to electronic cigarettes, saying new evidence has confirmed that vaping has...

National lung cancer screening program recommended in report

TSANZ says new evidence strengthens case against vaping for smoking cessation

Real world lung cancer screening adherence is lower than trial rates

Lung cancer overtaken by dementia as second leading cause of death in males

Lung screening is coming to Australia – the question is in what form

Why lung cancer patients don’t receive guideline recommended therapy

Lung cancer screening evidence contested at ERS 2020

ALK inhibitor suitable for first line therapy in NSCLC

Advanced mesothelioma: frontline chemoimmunotherapy shows promise in DREAM trial

Assisted dying scheme needs more respiratory specialists on board

Lung cancer patients with COVID-19 have 36% mortality rate: TERAVOLT

Lessons from NELSON study: implementation trials the next step in lung cancer screening

First positive results for dual immunotherapy in mesothelioma

Lung cancer detected at earlier stage with biomarker-based screening

Biomarker blood test may detect earlier stage disease in lung cancer screening

Dual immunotherapy approved for NSCLC

TSANZ comes out strongly against e-cigarettes

Lung cancer research faces shake-up after dramatic split of ALTG

KRAS mutation targetable for better outcomes in smokers with NSCLC

Podcast: Prof. Nick Pavlakis on key advances in lung cancer management over the past decade

Lung cancer screening in 2020: What does the evidence say?

Lung cancer outcomes gap still wide for Indigenous Australians

Call for lung cancer specialist nurse funding

Osimertinib could be new standard of care for EGFRm NSCLC

A/Prof Nick Pavlakis: how lung cancer care has changed in the COVID-19 pandemic

Lung cancer linked to higher mortality in COVID-19

Lung cancer conference: Associate Professor Nick Pavlakis on the steps to improving care

ALCC 2020: Lung cancer screening works – it’s time to do it

Case for targeted lung cancer screening bolstered by NELSON results, experts say

PBS broadens access to COPD triple therapy and lung cancer immunotherapy

Vaping backed for smoking cessation in ‘pragmatic’ new RACGP guidelines

Lung Foundation seeks help to counter Big Tobacco’s latest toxic product

Disappointing results for mesothelioma trial

Atezolizumab shows OS benefit over chemo in PD-L1 high NSCLC

First KRAS-targeted therapy for lung cancer shows promise

Vaping-NRT combination boosts smoking quit rates

Minister requests feasibility study for lung cancer screening

Lung cancer: personalised medicine to be delivered by ‘molecular champions’

PBS allows unrestricted pemetrexed use in first-line treatment of NSCLC

‘Non-expandable lung’ common finding in mesothelioma patients

Atezolizumab-based combination gets first line approval for metastatic NSCLC

1 in 4 patients with advanced NSCLC alive at 5 years with immunotherapy

Infographic shows modern day benefits and harms of lung cancer screening

National Dust Diseases Taskforce to be set up this year

Respiratory physician wins case against asbestos industry lobbyist

Professor Ian Yang: exploring coexisting COPD and lung cancer

Advanced lung cancer patients get real benefits from home exercise support

Functional decline at end of life shows ‘tipping point’ in respiratory patients

Woolcock’s lung cancer centre leader looks to microbiome

Room to improve care for stage lll NSCLC

RACP calls for urgent action on dust diseases recommendations

SABR the treatment of choice for inoperable stage 1 NSCLC

$4 million launch for National Strategic Action Plan for Lung Conditions

Lung cancer still diagnosed in emergency settings

CHEST Australia trial shows it’s an uphill challenge to detect lung cancer early

Crizotinib and osimertinib listed on PBS for lung cancer

Lung Foundation launches campaign to tackle lack of empathy for lung cancer

Lung cancer deaths still increasing

Lung cancer screening within 5 years – but will it target the right people?

Pembrolizumab gets PBS listing for first line treatment of advanced NSCLC

Key reforms needed to avoid disjointed care for lung cancer patients: LFA

Respiratory physician elected to Academy in recognition of medical research

Don’t look for lung cancers on coronary CT angiograms

Malignant pleural effusions: the jury is still out on definitive management

Deprescribing call for lung cancer patients taking unnecessary medicines

Big Tobacco vs Australia’s Plain Packaging

Young women with lung cancer face early menopause from chemo

Push to deregulate e-cigs in UK

Lung cancer patients benefit from brachytherapy palliation

Lung cancer diagnosis difficulties highlighted in NSW study

Have your say on National Strategic Action Plan for Lung Conditions

Lung cancer patients pay more than $20,000 in upfront fees

Palliative care group opposes opioid prescribing curbs

Row over lung cancer drug deal

Novel therapies begin to ‘outsmart’ ALK-positive NSCLC

Lung cancer’s other side effect: financial toxicity

Immune therapy benefits confirmed in NSCLC

Liquid biopsy could replace lung tissue biopsy: Australian trial

Checkpoint inhibitors show potential for first line use in NSCLC

Lung cancer screening hurdles become apparent in ILST

GPs unlikely to pick up certain cancers right away because its not the most likely diagnosis